SCHEMBL2260258

SCHEMBL2260258

CC(C)(C)OC(=O)Nc1ncccc1F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.46
NAMPT P43490 2/20 0.44
SYK P43405 1/20 0.43
ATR Q13535 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
CYP17A1 P05093 3/20 0.41
RORC P51449 1/20 0.40
RAB9A P51151 2/20 0.40
TRPV1 Q8NER1 1/20 0.40
NPC1 O15118 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
AAK1 Q2M2I8 1/20 0.37
STIM1 Q13586 1/20 0.37
ORAI1 Q96D31 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid Methyl Ester SCHEMBL31017385 0.92 METAP1 (0.41) METAP1NAMPTSYKATRMAPT
SCHEMBL31419186 0.85 GAA (0.47) METAP1NAMPTSYKATRMAPT
SCHEMBL27611635 0.85 METAP1 (0.46) METAP1NAMPTSYKATRCYP17A1
SCHEMBL27967000 0.83 RAB9A (0.49) METAP1NAMPTATRMAPTCYP17A1
SCHEMBL15266282 0.83 METAP1 (0.56) METAP1NAMPTATRCYP17A1RAB9A
SCHEMBL68279 0.83 RAB9A (0.54) METAP1MAPTHTTRAB9ANPC1
SCHEMBL29919656 0.83 RAB9A (0.54) METAP1MAPTHTTRAB9ANPC1
SCHEMBL5466767 0.82 LMNA (0.51) METAP1NAMPTATRTRPV1LMNA
SCHEMBL24666065 0.82 METAP1 (0.46) METAP1NAMPTATRHTTCYP17A1
SCHEMBL18803797 0.82 METAP1 (0.46) METAP1NAMPTATRCYP17A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-12-01 US disclosed
US-8058425-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-11-15 US disclosed
US-8022065-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2011-08-25 US disclosed
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS ELI LILLY AND COMPANY 2009-04-23 US disclosed
US-7491716-B2 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY (US) 2009-02-17 US disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed
EP-1483265-B1 PURINE DERIVATIVES AS KINASE INHIBITORS LILLY CO ELI (US) 2006-11-22 EP disclosed
US-20050090483-A1 Purine derivatives as kinase inhibitors ELI LILLY AND COMPANY 2005-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090483-A1 Purine derivatives as kinase inhibitors PNP, ADK, NME2 METAP1 1461/4885NAMPT 366/4885SYK 1261/4885
US-20110294792-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 METAP1 1461/4885NAMPT 366/4885SYK 1261/4885
US-20110207721-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 METAP1 1461/4885NAMPT 366/4885SYK 1261/4885
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 METAP1 434/4885NAMPT 324/4885SYK 4801/4885
US-20090105229-A1 PURINE DERIVATIVES AS KINASE INHIBITORS PNP, ADK, NME2 METAP1 1461/4885NAMPT 366/4885SYK 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.